1. Home
  2. MSDL vs SLRX Comparison

MSDL vs SLRX Comparison

Compare MSDL & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MSDL
  • SLRX
  • Stock Information
  • Founded
  • MSDL 2019
  • SLRX N/A
  • Country
  • MSDL United States
  • SLRX United States
  • Employees
  • MSDL N/A
  • SLRX N/A
  • Industry
  • MSDL
  • SLRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MSDL
  • SLRX Health Care
  • Exchange
  • MSDL NYSE
  • SLRX Nasdaq
  • Market Cap
  • MSDL 1.7B
  • SLRX 1.8M
  • IPO Year
  • MSDL N/A
  • SLRX N/A
  • Fundamental
  • Price
  • MSDL $19.39
  • SLRX $0.64
  • Analyst Decision
  • MSDL Hold
  • SLRX
  • Analyst Count
  • MSDL 5
  • SLRX 0
  • Target Price
  • MSDL $20.00
  • SLRX N/A
  • AVG Volume (30 Days)
  • MSDL 423.2K
  • SLRX 3.6M
  • Earning Date
  • MSDL 01-01-0001
  • SLRX 08-08-2025
  • Dividend Yield
  • MSDL 11.43%
  • SLRX N/A
  • EPS Growth
  • MSDL N/A
  • SLRX N/A
  • EPS
  • MSDL N/A
  • SLRX N/A
  • Revenue
  • MSDL N/A
  • SLRX N/A
  • Revenue This Year
  • MSDL $1,597.39
  • SLRX N/A
  • Revenue Next Year
  • MSDL $15.10
  • SLRX N/A
  • P/E Ratio
  • MSDL N/A
  • SLRX N/A
  • Revenue Growth
  • MSDL N/A
  • SLRX N/A
  • 52 Week Low
  • MSDL $17.59
  • SLRX $0.45
  • 52 Week High
  • MSDL $23.63
  • SLRX $7.20
  • Technical
  • Relative Strength Index (RSI)
  • MSDL 51.50
  • SLRX 41.73
  • Support Level
  • MSDL $18.84
  • SLRX $0.66
  • Resistance Level
  • MSDL $19.19
  • SLRX $0.90
  • Average True Range (ATR)
  • MSDL 0.26
  • SLRX 0.12
  • MACD
  • MSDL 0.03
  • SLRX -0.03
  • Stochastic Oscillator
  • MSDL 81.48
  • SLRX 16.46

About MSDL MORGAN STANLEY DIRECT LENDING FUND

Morgan Stanley Direct Lending Fund is a fund whose investment objective is to achieve attractive risk-adjusted returns via current income and to a lesser extent, capital appreciation by investing predominantly in directly originated senior secured term loans issued by U.S. middle-market companies backed by private equity sponsors. It invests predominantly in directly originated senior secured term loans including first lien senior secured term loans including unitranche loans and second lien senior secured term loans, with the balance of the investments expected to be in higher-yielding assets such as mezzanine debt, unsecured debt, equity investments and other opportunistic asset purchases.

About SLRX Salarius Pharmaceuticals Inc.

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Share on Social Networks: